FRANKLIN LAKES, N.J.,
Sept. 7, 2018 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today issued the following statement
regarding the sale of its Advanced Bioprocessing business to Thermo
Fisher Scientific:
"The sale of our Advanced Bioprocessing business will create
greater focus for our Life Sciences segment where BD has
outstanding opportunities to contribute significant innovation for
disease and therapy research and clinical diagnostics," said
Patrick Kaltenbach, president of
Life Sciences for BD. "BD remains committed to our customers in the
clinical, life sciences and industrial segments and will continue
to sell all of our media product offerings to these important
partners."
BD Advanced Bioprocessing has annualized revenue of
approximately $100 million. For
fiscal year 2018, BD estimates the contribution from the Advanced
Bioprocessing business to earnings per share of approximately
$0.13 to $0.15 on a full-year basis. The company expects
to record a tax gain on the transaction at the time of closing. The
transaction is subject to customary closing conditions and is
expected to close in early 2019.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help improve patient
outcomes, improve the safety and efficiency of clinicians' care
delivery process, enable laboratory scientists to better diagnose
disease and advance researchers' capabilities to develop the next
generation of diagnostics and therapeutics. BD has a presence in
virtually every country and partners with organizations around the
world to address some of the most challenging global health issues.
By working in close collaboration with customers, BD can help
enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. In 2017, BD welcomed C. R.
Bard and its products into the BD family. For more information on
BD, please visit bd.com.
FORWARD LOOKING STATEMENT
This press release contains
certain estimates and other forward-looking statements (as defined
under Federal securities laws) regarding the sale of BD's Advanced
Bioprocessing business and the impact on BD's performance,
including future earnings per share. Forward-looking statements can
be identified by the use of words such as "expect", "anticipate"
and similar words. All such statements are based on the current
expectations of BD management and involve a number of business
risks and uncertainties. A number of factors could cause actual
results to vary materially from any forward-looking statement,
including the risk that the transaction may not be completed or
that it will not be completed in the anticipated timeframe. The
forward-looking statements in this press release speak only as of
the date hereof, and we do not intend to update any forward-looking
statements to reflect events or circumstances after the date
hereof, except as required by applicable laws or regulations.
Contacts:
Troy
Kirkpatrick
BD Public
Relations
858.617.2361
troy.kirkpatrick@bd.com
|
Monique N.
Dolecki
BD Investor
Relations
201.847.5378
Monique_Dolecki@bd.com
|
View original
content:http://www.prnewswire.com/news-releases/bd-statement-on-divestiture-of-advanced-bioprocessing-business-300708675.html
SOURCE BD (Becton, Dickinson and Company)